ClinicalTrials.gg
Status unknownNCT04367441Updated Apr 29, 2020

Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects

A Phase 1 interventional study of 608 and Placebo in Moderate to Severe Plaque Psoriasis, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-29.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2019, registered Apr 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
134th of 182
62 · median 171
Started
2019
with 17 others
Phase 1
37 of 206
5 open now
Registered
56th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 134th largest by planned enrollment of the 182 interventional ones that give a count, is one of 18 that started in 2019, is one of 37 in phase 1, and was the 56th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This is a first-in-human, phase 1, single-center, randomized, double blinded, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, of 608 following subcutaneous injection in healthy subjects.

Read the detailed description

The study will consist of a 14-days screening period (-14\~-1 days); an observation period (7-14 days) and the follow-up period (71-91days); Subjects will be randomly assigned to seven group.

03

Conditions studied

  • Moderate to Severe Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 18 to 45 years;
  • Good health status (no significant clinical symptoms and signs and no clinical significance of abnormal laboratory test).
  • The body weight no less than 50 kg for male subjects and no less than 45 kg for female subjects. (BMI) = weight (kg)/square of height, ranging from 19-26kg/m2 (including the critical value)
  • Voluntary written ;
  • Being able to complete the study according to the requirements in the study protocol
  • The person who have undergone surgical treatment have fully recovered

Exclusion criteria

Exclusion Criteria:

  • Allergic constitution or history of allergy to two or more substances; Known to any biotherapy; Allergy to rubber or latex; Allergy to study drug or any components of study drug by investigator assessment
  • Participation in any other clinical study about drugs or medical instruments within 3 months prior to enroll, or subjects currently included in the study which are not scientifically or medically compatible with this study
  • Use of any medicine within 5 half-lives or less than 4 weeks prior to enroll (the longer of the two shall prevail)
  • Participation in any IL-17 antagonists at any time
  • Used vaccination or participation in any other clinical vaccination study within 12 weeks prior to enroll, or plan to use vaccine during the study or within 12 months after the study
  • Any major surgery within 8 weeks prior to enroll, or requiring such surgery during the study
  • Having history of any diseases, including but not limited to digestive system, cardiovascular system, respiratory system, urinary system, musculoskeletal system, endocrine system, nerves and mental system, hematological system, Immune diseases, abnormal metabolism, etc
  • History of or current Inflammatory Bowel Disease
  • Loss or donation of blood ≥200mL within 12 weeks prior to enroll, or receiving blood transfusion in recent 8 weeks; or plan to donate blood during the study
  • Positive antibody or positive treponema pallidum serum specific antibody;
  • Positive surface antigen, or positive hepatitis B core antibody and negative hepatitis B surface antibody
  • Positive antibody
  • History of or current lymphatic proliferative disease; Sign or symptom of lymphatic proliferative disease; History of or current malignant tumor
  • Serious infection (e.g., pneumonia, cellulitis) or varicella-zoster virus infection, hospitalization, infection using antibiotics by intravenous injection within 12 weeks prior to enroll; serious bone and joint infection witn 24 weeks prior to enroll; or happened artificial joint infections; any infection within 7 days (include chronic or local infection ,such as a local skin infection); or history of recurrent infections and prone to infections of the basic diseases ((including but not limited to herpes zoster virus (> 1 time) and herpes simplex virus infection); history of any immunological injuries(pneumocystis pneumonia, histoplasmosis, or coccidioidomycosis);
  • Having clinical evidence of active tuberculosis or suspected for active TB, or previous evidence of active TB but not received appropriate treatment or missing records; or latent tuberculosis infection at screening;
  • Known immune deficiency; or the subject with weakened immune system may have unacceptable risk if participating in this study
  • Pregnant, nursing, or planning pregnancy within 6 months(women) or planning to donate sperm or egg; pregnancy test positive; not use effective (details for appendix 5) or the partner of the men subject planned to have a baby within 6 months;
  • History of definite neurological or psychiatric disorders:such as epilepsy;
  • History of alcohol or substance abuse with 14 units of alcohol per week within 6 months (1 unit =12 ounce or 360mL beer/1.5 ounce or 45ml liquor with 40% alcohol/5 ounce or 150mL wine); positive of alcohol or substance abuse test;
  • Smoking more than 5 per day within 6 months prior to enroll
  • Chronic overdose of tea, coffee, or caffeinated beverages within 3 months (average more than 8 cups per day, 1 cup=250mL);having any food or beverages with alcohol / caffeine within 48 hours prior to administration (such as coffee, strong tea, cocoa, chocolate and so on); having any food or beverages with rich grapefruit, grapefruit juice or others effect on absorption distribution, metabolism, excretion;
  • insufficient understanding of the content and unwilling to comply with arrangement and other sides do not meet the inclusion criteria
  • Any other conditions, the subject was inappropriate to participate in the study by investigators evaluated (for example, weak or having a disease that prevents the subjects from completing the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    608

    8mg, 20mg, 40mg, 80mg, 120mg, 160mg, 200mg

    Drug: 608

  • Placebo comparator
    Placebo

    20mg, 40mg, 80mg, 120mg, 160mg, 200mg

    Drug: Placebo

Interventions

  • Drug608

    recombinant humanized anti-IL17A monoclonal antibody injection

  • DrugPlacebo

    auxiliary material of 608 include histidine, histidine hydrochloride, sucrose and polysorbate 80

06

What researchers measure

Primary outcomes

  1. AE/SAEs

    Incidence of treatment emergent AE/SAEs

    Time frame: From baseline through overall study (follow-up period: the arm of 8mg, 20mg,40mg with 71 days; 80mg, 120mg,160mg, 200mg with 91 days)

Secondary outcomes

  1. Cmax

    Maximum observed concentration (Cmax) of 608

    Time frame: From baseline through 71days/91day

  2. Tmax

    Time to Reach the Maximum Concentration After Drug Administration (Tmax) in 608 group

    Time frame: From baseline through 71days/91day

  3. AUClast

    Area Under the Serum Concentration-time Cure From Time Zero to the Time of Last Quantifiable Concentration (AUClast) in 608 group.

    Time frame: From baseline through 71days/91day

  4. AUCinf

    Area Under the Serum Concentration-time Curve From Time Zero to (AUCinf) in 608 group.

    Time frame: From baseline through 71days/91day

  5. CL

    Systemic Clearance From Serum Following Intravenous Administration (CL) in 608 group

    Time frame: From baseline through 71days/91day

  6. Vd

    Apparent volume of distribution (Vd) in 608 group

    Time frame: From baseline through 71days/91day

  7. T1/2

    Terminal Elimination Half-life (T1/2) in 608 group

    Time frame: From baseline through 71days/91day

  8. MRT

    Mean residence time (MRT) in 608 group

    Time frame: From baseline through 71days/91day

  9. λz

    Apparent terminal elimination rate constant (λz)in 608 group.

    Time frame: From baseline through 71days/91day

  10. Percentage of Participants With Anti-608 Antibodies

    Percentage of participants with treatment-emergent positive anti-608 antibodies and Neutralizing antibody;

    Time frame: From baseline through 71days/91day.

07

Study locations

1 of 1 sites recruiting
  • Public Health Clinical Center (Shanghai)
    Jinshan, Shanghai 201508, China
    Recruiting
    • Hongzhou Lu, PHD · Contact
    • Hongzhou LU · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Oct 2020, 11 months after the start.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 11 months is close to that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2020
First posted
Apr 29, 2020
StartActual
Nov 25, 2019
Primary completionEst.
Oct 31, 2020
CompletionEst.
Oct 31, 2020
Last update
Apr 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04367441
Responsible party
Sponsor
First posted
Apr 29, 2020
Start date
Nov 25, 2019
Primary completion
Oct 31, 2020 (estimated)
Completion
Oct 31, 2020 (estimated)
Last update
Apr 29, 2020

Study contacts

Hongzhou Lu, PhD
Contact
luhongzhou@fudan.edu.cn
(021)37990333-5278

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion